Stem-like CD4 T cells in tumors: an emerging framework for antitumor immunity

Recent studies have identified antigen-experienced TCF1⁺PD-1⁺ lineage-negative (lin^-) CD4 T cells in several tumor types. Strictly, stemness requires durable self-renewal and multipotent output demonstrated at the single-cell level; these criteria have not yet been established for an individual tumor-associated CD4 T cell. Operationally, this review uses "stem-like CD4 T cells" for TCF1⁺PD-1⁺ lin^- populations that lack canonical terminal TH1, TH2, TH17, and Treg commitment programs and show population-level persistence and multilineage output. Pending single-cell lineage tracing, these populations are best regarded as candidate progenitor-like states. Within the tumor microenvironment, their differentiation trajectory may influence antitumor immunity. Treg-mediated suppression, TGF-β signaling, metabolic stress, and limited IL-12 can restrain effector differentiation, whereas release of these constraints can permit TH1 output, CD8-supporting activity in tumor-draining lymph nodes, and direct MHC class II-restricted antitumor effects in selected models. Direct tumor evidence remains concentrated in a limited set of studies, while infection, autoimmunity, transplantation, and CD8 research provide contextual or cross-lineage support. This review therefore presents stem-like CD4 biology as an emerging framework and distinguishes established observations from working models.